

Aakash P Desai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3805030/publications.pdf>

Version: 2024-02-01

51
papers

2,392
citations

623734

14
h-index

223800

46
g-index

51
all docs

51
docs citations

51
times ranked

5713
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	13.7	1,395
2	COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. JCO Global Oncology, 2020, 6, 557-559.	1.8	258
3	Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine, 2020, 20, 100269.	7.1	102
4	Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer, 2021, 127, 1459-1468.	4.1	98
5	Crowdsourcing a crisis response for COVID-19 in oncology. Nature Cancer, 2020, 1, 473-476.	13.2	66
6	COVID-19 and Cancer. JAMA Oncology, 2021, 7, 1882.	7.1	42
7	Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. Lung Cancer, 2022, 163, 96-106.	2.0	35
8	Endpoints used in phase III randomized controlled trials of treatment options for COVID-19. EClinicalMedicine, 2020, 23, 100403.	7.1	32
9	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. JAMA Network Open, 2022, 5, e2216183.	5.9	27
10	The CoVIDaCTE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDaCTE. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	3.8	23
11	Hallmarks of RET and Co-occurring Genomic Alterations in RET-aberrant Cancers. Molecular Cancer Therapeutics, 2021, 20, 1769-1776.	4.1	23
12	Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600E Mutant Tumors. Molecular Cancer Therapeutics, 2022, 21, 871-878.	4.1	23
13	Change in Reporting of USMLE Step 1 Scores and Potential Implications for International Medical Graduates. JAMA - Journal of the American Medical Association, 2020, 323, 2015.	7.4	22
14	Financial toxicity in hematological malignancies: a systematic review. Blood Cancer Journal, 2022, 12, 74.	6.2	22
15	Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. JCO Oncology Practice, 2021, 17, e1293-e1302.	2.9	18
16	Immunological alternation in COVID-19 patients with cancer and its implications on mortality. OncoImmunology, 2021, 10, 1854424.	4.6	18
17	Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020. JAMA Network Open, 2022, 5, e2144923.	5.9	14
18	5-Fluorouracil Rechallenge After Cardiotoxicity. American Journal of Case Reports, 2020, 21, e924446.	0.8	13

#	ARTICLE	IF	CITATIONS
19	Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress?. International Journal of Cancer, 2021, 148, 429-436.	5.1	12
20	Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019. Cancer, 2020, 126, 3742-3749.	4.1	11
21	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2021, , .	1.1	11
22	Prognostic value of hypoalbuminemia at diagnosis in <i>de novo</i> non-M3 acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 641-649.	1.3	10
23	Demographic and Socioeconomic Disparities Among Cancer Survivors in Clinical Trials Participation, USA, 2016â€“2018. Journal of Cancer Education, 2022, 37, 88-90.	1.3	9
24	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. Case Reports in Oncological Medicine, 2019, 2019, 1-6.	0.3	8
25	Crowdsourcing in Crisis: Rising to the Occasion. JCO Clinical Cancer Informatics, 2020, 4, 551-554.	2.1	8
26	Quantifying risk factors for ischemic colitis: A nationwide, retrospective cohort study. Indian Journal of Gastroenterology, 2020, 39, 398-404.	1.4	8
27	Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer. JAMA Oncology, 2021, 7, 227.	7.1	7
28	Cardiovascular risk management in cancer survivors: Are we doing it right?. World Journal of Clinical Oncology, 2021, 12, 144-149.	2.3	7
29	Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis. Ecanermedicalscience, 2020, 14, 1091.	1.1	7
30	Fall in US cancer death rates: Time to pop the champagne?. EclinicalMedicine, 2020, 19, 100279.	7.1	6
31	Progress in molecular feature of smoldering mantle cell lymphoma. Experimental Hematology and Oncology, 2021, 10, 41.	5.0	6
32	Economic Cost and Sustainability of Oral Therapies in Precision Oncology. JCO Oncology Practice, 2022, 18, e1247-e1254.	2.9	6
33	Aligning Cancer Clinical Trials With Cancer Burden. JAMA Oncology, 2021, 7, 357.	7.1	5
34	Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis. Blood, 2020, 136, 28-30.	1.4	5
35	Reversible Ocular Toxicity of Oxaliplatin: A Case Report. Cureus, 2019, 11, e4582.	0.5	5
36	Alteration of serum markers in COVIDâ€19 and implications on mortality. Clinical and Translational Medicine, 2020, 10, e119.	4.0	4

#	ARTICLE	IF	CITATIONS
37	COVID-19 and Global Oncology: A Year in Review. JCO Global Oncology, 2021, 7, 797-801.	1.8	4
38	HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma. Journal of Oncology Pharmacy Practice, 2021, 27, 1806-1809.	0.9	4
39	Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap?. JAMA Oncology, 2021, 7, 173.	7.1	3
40	Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?. Oncology, 2021, 35, 390-396.	0.5	3
41	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. Blood, 2020, 136, 56-58.	1.4	3
42	Clinical Trial End Points in Severe COVID-19. Mayo Clinic Proceedings, 2020, 95, 1578-1580.	3.0	2
43	COVID-19 in Older Individuals with Cancer: Problem and Potential Solutions. Cancer Investigation, 2021, 39, 214-216.	1.3	2
44	Clinical Trial Access in Low- and Middle-Income Countries: A Case Study on India. Cancer Investigation, 2021, 39, 685-689.	1.3	2
45	Secondary Immune Thrombocytopenic Purpura in Renal Cell Cancer: A Paraneoplastic Syndrome. Cureus, 2019, 11, e4398.	0.5	2
46	Calvarial osteomyelitis and intracranial extension post-Mohs micrographic surgery. BMJ Case Reports, 2018, 2018, bcr-2018-224861.	0.5	1
47	Zieve's Syndrome: an Unusual Cause of Anemia. SN Comprehensive Clinical Medicine, 2020, 2, 349-354.	0.6	0
48	The Great Breast Cancer Screening Conundrum. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 376-379.	0.2	0
49	The Sustainability of Price Dynamics in Precision Hematology. Blood, 2021, 138, 114-114.	1.4	0
50	Level of Scientific Evidence Underlying Recommendations from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?. Blood, 2020, 136, 32-32.	1.4	0
51	Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022. Cancer Investigation, 2022, 40, 577-589.	1.3	0